Brain cancer patient survival remains challenging for Neurosurgeons, Neuro-oncologists, Radiation Oncologists and Basic Scientists. Brain cancer has one of the highest mortality rates in children and adults, which are primarily due to chemoresistance and/or tumor recurrence. Recent studies have identified many transcription factors, including homeobox genes, bHLH genes, forkhead genes, Sox genes, Myc, nuclear factor genes and cell signaling pathways such as Sonic hedgehog, Notch and Wnt. Stem cell markers including Nanog, Oct and CD15 have been identified to screen novel molecules as future therapeutic approaches. In addition, epigenetic regulation of these factors is also driving brain tumor cells to acquire chemoresistance.
However, brain cancer patients’ survival is still a milestone for the Neuro-oncology community. Studies have identified that cell signalling pathways, downstream targets of transcription factors, stem cell markers, and epigenetic regulation are mainly responsible and the driving force for chemoresistance and tumour recurrence. Therefore, it is important to identify and address these transcription factors, stem cell markers and epigenetic regulators as a potential therapeutic targets for novel brain cancer therapies.
This Research Topic welcomes all research focused on the role of transcription factors, stem cell markers and associated cell signalling pathways in brain cancer linked to chemoresistance and tumour recurrence. Moreover, it also expands the scope for the role of all types of epigenetic regulation in chemoresistance of brain cancer towards new drug discovery for brain cancer treatments.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (clinical cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Brain cancer patient survival remains challenging for Neurosurgeons, Neuro-oncologists, Radiation Oncologists and Basic Scientists. Brain cancer has one of the highest mortality rates in children and adults, which are primarily due to chemoresistance and/or tumor recurrence. Recent studies have identified many transcription factors, including homeobox genes, bHLH genes, forkhead genes, Sox genes, Myc, nuclear factor genes and cell signaling pathways such as Sonic hedgehog, Notch and Wnt. Stem cell markers including Nanog, Oct and CD15 have been identified to screen novel molecules as future therapeutic approaches. In addition, epigenetic regulation of these factors is also driving brain tumor cells to acquire chemoresistance.
However, brain cancer patients’ survival is still a milestone for the Neuro-oncology community. Studies have identified that cell signalling pathways, downstream targets of transcription factors, stem cell markers, and epigenetic regulation are mainly responsible and the driving force for chemoresistance and tumour recurrence. Therefore, it is important to identify and address these transcription factors, stem cell markers and epigenetic regulators as a potential therapeutic targets for novel brain cancer therapies.
This Research Topic welcomes all research focused on the role of transcription factors, stem cell markers and associated cell signalling pathways in brain cancer linked to chemoresistance and tumour recurrence. Moreover, it also expands the scope for the role of all types of epigenetic regulation in chemoresistance of brain cancer towards new drug discovery for brain cancer treatments.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (clinical cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
